[2,3,4-Trihydroxy-5-(hydroxymethyl)oxolan-2-yl]methyl dihydrogen phosphate

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: [2,3,4-Trihydroxy-5-(hydroxymethyl)oxolan-2-yl]methyl dihydrogen phosphate
• 化学式: C₆H₁₃O₉P
• 分子量: 260.138
• InChiKey: RHKKZBWRNHGJEZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.9
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  157
• 氢给体数：
  6
• 氢受体数：
  9

文献信息

• NOVEL COCRYSTALLIZATION
  申请人：CHILDS Scott L.

  公开号：US20110257430A1

  公开（公告）日：2011-10-20

  The present disclosure relates to novel cocrystals and novel methods for cocrystallization. In particular, the disclosure includes cocrystals comprising a salt of an active agent, such as a chloride salt of an active pharmaceutical ingredient. The present disclosure also relates to methods of preparing cocrystals and methods for screening for solid state phases.

  本公开涉及新型共晶体及新型共晶化方法。具体来说，公开包括包含活性物质的盐的共晶体，例如活性药物成分的氯化物盐。本公开还涉及制备共晶体的方法以及筛选固态相的方法。
• Screening for solid forms by ultrasound crystallization and cocrystallization using ultrasound
  申请人：APTUIT (KANSAS CITY), LLC

  公开号：EP2292585A1

  公开（公告）日：2011-03-09

  The present invention relates to cocrystals of fluoxctinc hydrochloride and benzoic acid. Furthermore, methods are provided for producing the cocrystals.

  本发明涉及盐酸氟辛酸和苯甲酸的共晶体。此外，还提供了生产这种共晶体的方法。
• Diagnosis and treatment of neonatal encephalopathy
  申请人：InfanDx AG

  公开号：US10514383B2

  公开（公告）日：2019-12-24

  Metabolites and signatures (panels) of metabolites are applicable as biomarkers in clinical diagnosis, in particular for neonatal encephalopathy. They are useful tools in differential clinical diagnosis for early detection of brain injury, determination of brain areas affected by the insults and prediction of adverse neurological outcome and may also be applied in diagnosing disease progression and treatment effect. An in vitro method for predicting the likelihood of neonatal encephalopathy of distinct brain areas, identification of affected brain area(s) of neonatal encephalopathy and risk of brain damage and prognosis and neurological outcome due to identification of the type and extent of damage of distinct brain tissues, in particular of hippocampus and/or basal ganglia, is provided.

  代谢物和代谢物特征（组）可作为生物标记物用于临床诊断，尤其是新生儿脑病的诊断。它们是临床鉴别诊断的有用工具，可用于早期发现脑损伤、确定受损伤影响的脑区和预测不良神经系统结果，还可用于诊断疾病进展和治疗效果。本研究提供了一种体外方法，用于预测不同脑区发生新生儿脑病的可能性、确定新生儿脑病的受影响脑区、脑损伤风险以及由于确定不同脑组织（特别是海马和/或基底节）的损伤类型和程度而导致的预后和神经系统结局。
• SCREENING FOR SOLID FORMS BY ULTRASOUND CRYSTALLIZATION AND COCRYSTALLIZATION USING ULTRASOUND
  申请人：Childs Scott L.

  公开号：US20110251426A1

  公开（公告）日：2011-10-13

  The present disclosure relates to crystallizing a chemical substance(s) using ultrasound. Methods are provided for screening a chemical substance according to its solid forms by using ultrasound to generate new or unusual solid forms. Methods are also provided for crystallizing a chemical substance by novel techniques that include sonication. The present disclosure also relates to cocrystallization using ultrasound. Methods are provided for preparing cocrystals of an active agent and a guest by sonicating and crystallizing. Methods are also provided for screening a sample according to solid state phases (such as cocrystals and salts) and include generating a cocrystal from the sample using ultrasound.
• Method and Use of Metabolites for the Diagnosis and Differentiation of Neonatal Encephalopathy
  申请人：InfanDx AG

  公开号：US20140308687A1

  公开（公告）日：2014-10-16

  Metabolites and signatures (panels) of metabolites are applicable as biomarkers in clinical diagnosis, in particular for neonatal encephalopathy. They are useful tools in differential clinical diagnosis for early detection of brain injury, determination of brain areas affected by the insults and prediction of adverse neurological outcome and may also be applied in diagnosing disease progression and treatment effect. An in vitro method for predicting the likelihood of neonatal encephalopathy of distinct brain areas, identification of affected brain area(s) of neonatal encephalopathy and risk of brain damage and prognosis and neurological outcome due to identification of the type and extent of damage of distinct brain tissues, in particular of hippocampus and/or basal ganglia, is provided.